It is becoming clear that heterogeneity in cancer cell cycles corresponds to variability of response to therapies targeting cyclin dependent kinases (CDKs). Here, the authors investigate CDK2-dependancy and response to CDK2 inhibition across different cancers, identifying markers of sensitivity and combinatorial therapeutic strategies.
- Vishnu Kumarasamy
- Jianxin Wang
- Erik S. Knudsen
